AEterna Zentaris (AEZS) Pops As Article Makes Case for 200% to 300% Upside
Tweet
Share
E-mailGet Alerts AEZS Hot Sheet
Join SI Premium – FREE
Æterna Zentaris, Inc. (Nasdaq: AEZS) shares are rocking today, following a bullish article on Seeking Alpha. The stock popped about 4.7% to $1.79, but has since receded a little.
The article highlights five key points that could still pack a potential 200% to 300% of upside into the stock. First, the author highlights that AEZS is in a healthy cash position, enough to fund upcoming trials and filings. They continue that AEZS is planning a New Drug Application with the U.S. FDA for Solorel, which is currently in Phase 3 testing and under a Special Protocol Assessment (SPA) with the FDA.
Further, perifisone is also in Phase 3, and has SPA, orphan-drug designation, and Fast-Track review from the FDA. An NDA filing is expected in 2012
Fourth, AEZS-108 recently completed a Phase 2 for endometrial cancer, which produced positive results. The company also initiated studies in other cancers.
Finally, the article notes that AEZS executives are currently seeking an Asian partner, which could garner better terms than they would find in the U.S. market.
The article highlights five key points that could still pack a potential 200% to 300% of upside into the stock. First, the author highlights that AEZS is in a healthy cash position, enough to fund upcoming trials and filings. They continue that AEZS is planning a New Drug Application with the U.S. FDA for Solorel, which is currently in Phase 3 testing and under a Special Protocol Assessment (SPA) with the FDA.
Further, perifisone is also in Phase 3, and has SPA, orphan-drug designation, and Fast-Track review from the FDA. An NDA filing is expected in 2012
Fourth, AEZS-108 recently completed a Phase 2 for endometrial cancer, which produced positive results. The company also initiated studies in other cancers.
Finally, the article notes that AEZS executives are currently seeking an Asian partner, which could garner better terms than they would find in the U.S. market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
- Hunterbrook bullish on Modine Manufacturing (MOD)
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
